Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
de Bruin M, Kunz P, Sharma V, Norton J, Bastidas J, Chang D, Koong A, Koong A, Balise R, Ford J, Fisher G. Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15674-e15674. DOI: 10.1200/jco.2009.27.15_suppl.e15674.Peer-Reviewed Original ResearchStanford Cancer CenterGEJ cancerAdjuvant chemoradiotherapyRetrospective reviewCycles of carboplatinPercentage of patientsGastroesophageal junction cancerGastroesophageal junction adenocarcinomaStandard of careExternal beam radiotherapyInfusional 5FUModified regimenPo bidPositive gastricResectable gastricAdjuvant treatmentCurative intentCurative resectionGastrointestinal toxicityMean followStage IBStage IIIAStage IIIBJunction cancerOverall survivalCarboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
Kunz P, de Bruin M, Balise R, Fisher G, Ford J. Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15686-e15686. DOI: 10.1200/jco.2009.27.15_suppl.e15686.Peer-Reviewed Original ResearchStanford Cancer CenterGastroesophageal junction cancerMetastatic gastricJunction cancerRetrospective reviewPossible treatment-related deathSingle-institution retrospective reviewCarboplatin AUC 6Regimen of carboplatinCycles of chemotherapyMedian overall survivalTreatment-related deathsStandard chemotherapy regimenFourty-five patientsGastroesophageal junction adenocarcinomaFluoropyrimidine-based treatmentSignet ring featuresAUC 6Chemotherapy-naïvePo bidChemotherapy regimenOnly patientsOverall survivalJunction adenocarcinomaMedian age